Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8044)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Feb 24, 2021 (publication date) through Apr 3, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Peravali M, Gomes-Lima C, Tefera E, Baker M, Sherchan M, Farid S, Burman K, Constantinescu F, Veytsman I. Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses. World J Clin Oncol 2021; 12(2): 103-114 [PMID: 33680877 DOI: 10.5306/wjco.v12.i2.103] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v12/i2/103.htm |
| Number | Citing Articles |
| 1 |
Xiao Hu, Jeffrey H. Lin, Stacey Pan, Yana V. Salei, Susan K. Parsons. The real-world insights on the use, safety, and outcome of immune-checkpoint inhibitors in underrepresented populations with lung cancer. Cancer Treatment and Research Communications 2024; 40: 100833 doi: 10.1016/j.ctarc.2024.100833
|
| 2 |
Akhil Rekulapelli, Lucas E. Flausino, Gayatri Iyer, Rajesh Balkrishnan. Effectiveness of immunological agents in non‐small cell lung cancer. Cancer Reports 2023; 6(1) doi: 10.1002/cnr2.1739
|
| 3 |
Pranav M. Patel, Utibe R. Essien, Laura Happe. Pharmacoequity measurement framework: A tool to reduce health disparities. Journal of Managed Care & Specialty Pharmacy 2024; : 1 doi: 10.18553/jmcp.2025.24298
|
| 4 |
Raymond U. Osarogiagbon, Helmneh M. Sineshaw, Joseph M. Unger, Ana Acuña-Villaorduña, Sanjay Goel. Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes. American Society of Clinical Oncology Educational Book 2021; (41): 66 doi: 10.1200/EDBK_323523
|
| 5 |
Vidya Sankar Viswanathan, Amit Gupta, Anant Madabhushi. Novel Imaging Biomarkers to Assess Oncologic Treatment–Related Changes. American Society of Clinical Oncology Educational Book 2022; (42): 687 doi: 10.1200/EDBK_350931
|
| 6 |
Astha Thakkar, Michelly Abreu, Kith Pradhan, R. Alejandro Sica, Aditi Shastri, Noah Kornblum, Nishi Shah, Ioannis Mantzaris, Kira Gritsman, Eric Feldman, Richard Elkind, Susan Green-Lorenzen, Amit Verma, Ira Braunschweig, Mendel Goldfinger. Efficacy and safety of CAR-T cell therapy in minorities. Bone Marrow Transplantation 2022; 57(7): 1187 doi: 10.1038/s41409-022-01670-1
|
| 7 |
Sean Miller, Ralph Jiang, Matthew Schipper, Lars G Fritsche, Garth Strohbehn, Beth Wallace, Daria Brinzevich, Virginia Falvello, Benjamin H McMahon, Rafael Zamora-Resendiz, Nithya Ramnath, Xin Dai, Kamya Sankar, Donna M Edwards, Steven G Allen, Shinjae Yoo, Silvia Crivelli, Michael D Green, Alex K Bryant. Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study. The Lancet Oncology 2024; 25(12): 1666 doi: 10.1016/S1470-2045(24)00528-X
|
| 8 |
Avital Klein-Brill, Shlomit Amar-Farkash, Keren Rosenberg-Katz, Ronen Brenner, Jürgen C. Becker, Dvir Aran. Comparative efficacy of combined CTLA-4 and PD-1 blockade vs. PD-1 monotherapy in metastatic melanoma: a real-world study. BJC Reports 2024; 2(1) doi: 10.1038/s44276-024-00041-1
|
| 9 |
Annie Chang, Raja M Flores, Emanuela Taioli. Unequal racial distribution of immunotherapy for late-stage non–small cell lung cancer. JNCI: Journal of the National Cancer Institute 2023; 115(10): 1224 doi: 10.1093/jnci/djad132
|
| 10 |
Akito Hata, Shunichiro Iwasawa, Yusuke Sasaki, Kosei Tajima, Yasutaka Chiba. A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients. Advances in Therapy 2024; 41(9): 3520 doi: 10.1007/s12325-024-02921-x
|
| 11 |
Jeffrey Shi Kai Chan, Pias Tang, Teddy Tai Loy Lee, Oscar Hou In Chou, Yan Hiu Athena Lee, Guoliang Li, Fung Ping Leung, Wing Tak Wong, Tong Liu, Gary Tse. Association between immune checkpoint inhibitors and myocardial infarction in Asians: A population‐based self‐controlled case series. Cancer Medicine 2023; 12(8): 9541 doi: 10.1002/cam4.5729
|
| 12 |
Amr Radwan, Chinmay T Jani, Omar Al Omari, Mohini Patel, Laura Burns, Zoe Mackay, Liuping Li, Kiana Mahdaviani, Arielle Davidson, Janice Weinberg, Peter C Everett, Kei Suzuki, Kimberley S Mak, Matthew H Kulke, Umit Tapan. The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients. The Oncologist 2025; 30(3) doi: 10.1093/oncolo/oyae279
|
| 13 |
Jeffrey Shi Kai Chan, Ishan Lakhani, Teddy Tai Loy Lee, Oscar Hou In Chou, Yan Hiu Athena Lee, Yiu Ming Cheung, Hoi Wa Yeung, Pias Tang, Kenrick Ng, Edward Christopher Dee, Tong Liu, Wing Tak Wong, Gary Tse, Fung Ping Leung. Cardiovascular Outcomes and Hospitalizations in Asian Patients Receiving Immune Checkpoint Inhibitors: A Population-based Study. Current Problems in Cardiology 2023; 48(1): 101380 doi: 10.1016/j.cpcardiol.2022.101380
|
| 14 |
Tsutomu Anraku, Hideki Hashidate, Tomoyuki Imai, Yoshiaki Kawakami. Successful treatment of immune‐related cystitis with bladder hydrodistension. IJU Case Reports 2023; 6(4): 211 doi: 10.1002/iju5.12588
|
| 15 |
Pranav M. Patel, Utibe R. Essien, Laura Happe. Pharmacoequity measurement framework: A tool to reduce health disparities. Journal of Managed Care & Specialty Pharmacy 2025; 31(2): 214 doi: 10.18553/jmcp.2025.31.2.214
|
| 16 |
Gianluca Nazzaro, Stefano Buffon, Serena Giacalone, Carlo Alberto Maronese, Angelo Valerio Marzano. Skin manifestations associated with checkpoint inhibitors. JEADV Clinical Practice 2022; 1(2): 73 doi: 10.1002/jvc2.27
|
| 17 |
Liyan Liu, Yilong Yan, Yuqiao Wang, Ziming Li, Li Yang, Kefu Yu, Zhigang Zhao. Comparative efficacy and safety of first‑line PD‑1/PD‑L1 inhibitors in immunotherapy for non‑small cell lung cancer: A network meta‑analysis. Oncology Letters 2025; 29(3) doi: 10.3892/ol.2025.14903
|